Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb Induction and Extension Study of RO7837195 in Moderately to Severely Active Ulcerative Colitis
jRCT2041250143Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing RO7837195 with Matched Placebo (2 arms). Primary endpoint: Clinical Remission at Week 12. Started Feb 2026; status: recruiting.
02
Drugs
RO7837195
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2041250143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250143.